Featured Research

from universities, journals, and other organizations

Schizophrenia Patients Who Are Likely To Receive Depot Medication Identified

Date:
April 30, 2007
Source:
Tulane University
Summary:
A recent report has identified a unique subgroup of schizophrenia patients in the United States who tend to receive depot antipsychotic medications.

A report in the April 2007 issue of Psychiatric Services has identified a unique subgroup of schizophrenia patients in the United States who tend to receive depot antipsychotic medications.

Patients with schizophrenia can improve with long-term treatment, but they may relapse if they do not follow antipsychotic medication regimens. Patient nonadherence to oral medication due to disorganization or disaffection with treatment has been difficult for clinicians to predict. Depot medications are administered by injection every two to four weeks, eliminating the need for daily oral dosing.

Use of depot medication for patients in the identified subgroup may help reduce relapses among these patients, the study suggests. This unique group of patients is more likely to include African-Americans and persons who are less likely to be veterans, have had previous psychiatric hospitalizations, were more likely to have been arrested, use alcohol and illicit substances, and show psychotic symptoms and disorganized thinking.

The study, “Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotic or Oral Antipsychotic for Schizophrenia,” led by Lizheng Shi, professor of health systems management at Tulane University School of Public Health and Tropical Medicine, examined data from a large randomized study on the treatment of 2,327 schizophrenia patients in the United States between July 1997 and Sept. 2003.

Co-authors of the study are: Haya Ascher-Svanum, Baojin Zhu, Douglas Faries, and William Montgomery, Eli Lilly and Co.; Stephen R. Marder, West Los Angeles Veterans Affairs Medical Center, Los Angeles, Calif. and the School of Medicine of the University of California–Los Angeles.


Story Source:

The above story is based on materials provided by Tulane University. Note: Materials may be edited for content and length.


Cite This Page:

Tulane University. "Schizophrenia Patients Who Are Likely To Receive Depot Medication Identified." ScienceDaily. ScienceDaily, 30 April 2007. <www.sciencedaily.com/releases/2007/04/070426123102.htm>.
Tulane University. (2007, April 30). Schizophrenia Patients Who Are Likely To Receive Depot Medication Identified. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2007/04/070426123102.htm
Tulane University. "Schizophrenia Patients Who Are Likely To Receive Depot Medication Identified." ScienceDaily. www.sciencedaily.com/releases/2007/04/070426123102.htm (accessed July 28, 2014).

Share This




More Mind & Brain News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com
University Quiz Implies Atheists Are Smarter Than Christians

University Quiz Implies Atheists Are Smarter Than Christians

Newsy (July 25, 2014) An online quiz from a required course at Ohio State is making waves for suggesting atheists are inherently smarter than Christians. Video provided by Newsy
Powered by NewsLook.com
Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins